Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

NCT06693128 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

Interventions

DRUG: Camrelizumab
DRUG: Apatinib
DRUG: S-1, Oxaliplatin

Sponsor

Ruijin Hospital